Daniela Bond-Smith

Dr. Daniela Bond-Smith


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 October 2020 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
JKJudith M. Katzenellenbogen
Judith M. Katzenellenbogen
DBDaniela Bond-Smith
Daniela Bond-Smith
RSRebecca J. Seth
Rebecca J. Seth
KDKaren Dempsey
Karen Dempsey
JCJeffrey Cannon
Jeffrey Cannon
ARAnna P. Ralph
Anna P. Ralph
Background: In 2018, the World Health Organization prioritized control of acute rheumatic fever (ARF) and rheumatic heart disease (RHD), including disease surveillance. We developed strategies for estimating contemporary ARF/RHD incidence and prevalence in Australia (2015–2017) by age group, sex, and region for Indigenous and non‐Indigenous Australians based on innovative, direct methods. Methods and Results: This population‐based study used linked administrative data from 5 Australian jurisdictions. A cohort of ARF (age <45 years) and RHD cases (<55 years) were sourced from jurisdictional ARF/RHD registers, surgical registries, and inpatient data. We developed robust methods for epidemiologic case ascertainment for ARF/RHD. We calculated age‐specific and age‐standardized incidence and prevalence. Age‐standardized rate and prevalence ratios compared disease burden between demographic subgroups. Of 1425 ARF episodes, 72.1% were first‐ever, 88.8% in Indigenous people and 78.6% were aged <25 years. The age‐standardized ARF first‐ever rates were 71.9 and 0.60/100 000 for Indigenous and non‐Indigenous populations, respectively (age‐standardized rate ratio=124.1; 95% CI, 105.2–146.3). The 2017 Global Burden of Disease RHD prevalent counts for Australia (<55 years) underestimate the burden (1518 versus 6156 Australia‐wide extrapolated from our study). The Indigenous age‐standardized RHD prevalence (666.3/100 000) was 61.4 times higher (95% CI, 59.3–63.5) than non‐Indigenous (10.9/100 000). Female RHD prevalence was double that in males. Regions in northern Australia had the highest rates. Conclusions: This study provides the most accurate estimates to date of Australian ARF and RHD rates. The high Indigenous burden necessitates urgent government action. Findings suggest RHD may be underestimated in many high‐resource settings. The linked data methods outlined here have potential for global applicability.

1 January 2019 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
DBDaniela Bond-Smith
Daniela Bond-Smith
JSJennifer Stone
Jennifer Stone
Mammographic density (MD) is an established predictor of breast cancer risk. However, there is limited information on the robustness of the risk associations for different study designs and the associated methodologic challenges. Our analysis includes 165 samples from studies published since 2006. We use a weakly informative Bayesian approach to avoid unduly optimistic estimates of uncertainty, as found in the previous literature. We find that the existing consensus from previous review studies has underestimated the strength and precision of MD as a risk marker. Moreover, although much of the published literature is based on categorical measurement of MD, there are tangible advantages in using continuous data in terms of estimate precision and relevance for different patient populations. Estimates based on the percentage of MD are more precise for lower density women, whereas absolute MD has advantages for higher density. We show that older results might not be a good proxy for current and future findings, and it would be pertinent to adjust clinical interpretations based on the older data. Using an appropriate estimation method cognizant of the importance of heterogeneity is critical to obtaining reliable and robust clinical findings that are relevant for broad patient populations.

1 November 2019 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
JKJudith M Katzenellenbogen
Judith M Katzenellenbogen
DBDaniela Bond-Smith
Daniela Bond-Smith
RSRebecca J Seth
Rebecca J Seth
KDKaren Dempsey
Karen Dempsey
JCJeffrey Cannon
Jeffrey Cannon
DBDawn Bessarab
Dawn Bessarab
Purpose: Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) persist as public health issues in developing countries and among disadvantaged communities in high-income countries, with rates in Aboriginal and Torres Strait Islander peoples in Australia among the highest recorded globally. A robust evidence base is critical to support policy recommendations for eliminating RHD, but available data are fragmented and incomplete. The End RHD in Australia: Study of Epidemiology (ERASE) Project aims to provide a comprehensive database of ARF and RHD cases in Australia as a basis for improved monitoring and to assess prevention and treatment strategies. The objective of this paper is to describe the process for case ascertainment and profile of the study cohort. Patients and methods: The ERASE database has been built using linked administrative data from RHD registers, inpatient hospitalizations, and death registry data from 2001 to 2017 (mid-year). Additional linked datasets are available. The longitudinal nature of the data is harnessed to estimate onset and assess the progression of the disease. To accommodate systematic limitations in diagnostic coding for RHD, hospital-only identified RHD has been determined using a purposefully developed prediction model. Results: Of 132,053 patients for whom data were received, 42,064 are considered true cases of ARF or RHD in the study period. The patient population under 60 years in the compiled dataset is more than double the number of patients identified in ARF/RHD registers (12,907 versus 5049). Non-registered patients were more likely to be older, non-Indigenous, and at a later disease stage. Conclusion: The ERASE Project has created an unprecedented linked administrative database on ARF and RHD in Australia. These data provide a critical baseline for efforts to end ARF/RHD in Australia. The methodological work conducted to compile this database resulted in significant improvements in the robustness of epidemiological estimates and entails valuable lessons for ARF/RHD research globally.

5 May 2023 in Chest
Verified
Journal Article
Closed access
RMRoss J. Marriott
Ross J. Marriott
BSBhajan Singh
Bhajan Singh
NMNigel McArdle
Nigel McArdle
EDEllie Darcey
Ellie Darcey
SKStuart King
Stuart King
GCGemma Cadby
Gemma Cadby

31 December 2019 in BMJ Open
Verified
Journal Article
Open access
PDF file
EDEvenda Dench
Evenda Dench
DBDaniela Bond-Smith
Daniela Bond-Smith
EDEllie Darcey
Ellie Darcey
GLGrant Lee
Grant Lee
YAYe K Aung
Ye K Aung
JSJennifer Stone
Jennifer Stone
Introduction For women of the same age and body mass index, increased mammographic density is one of the strongest predictors of breast cancer risk. There are multiple methods of measuring mammographic density and other features in a mammogram that could potentially be used in a screening setting to identify and target women at high risk of developing breast cancer. However, it is unclear which measurement method provides the strongest predictor of breast cancer risk. Methods and analysis The measurement challenge has been established as an international resource to offer a common set of anonymised mammogram images for measurement and analysis. To date, full field digital mammogram images and core data from 1650 cases and 1929 controls from five countries have been collated. The measurement challenge is an ongoing collaboration and we are continuing to expand the resource to include additional image sets across different populations (from contributors) and to compare additional measurement methods (by challengers). The intended use of the measurement challenge resource is for refinement and validation of new and existing mammographic measurement methods. The measurement challenge resource provides a standardised dataset of mammographic images and core data that enables investigators to directly compare methods of measuring mammographic density or other mammographic features in case/control sets of both raw and processed images, for the purposes of the comparing their predictions of breast cancer risk. Ethics and dissemination Challengers and contributors are required to enter a Research Collaboration Agreement with the University of Melbourne prior to participation in the measurement challenge. The Challenge database of collated data and images are stored in a secure data repository at the University of Melbourne. Ethics approval for the measurement challenge is held at University of Melbourne (HREC ID 0931343.3).

1 July 2020 in Clinical Epidemiology
Verified
Journal Article
Open access
PDF file
DBDaniela Bond-Smith
Daniela Bond-Smith
RSR Seth
R Seth
NKN de Klerk
N de Klerk
LNL Nedkoff
L Nedkoff
MAM Anderson
M Anderson
JKJm Katzenellenbogen
Jm Katzenellenbogen
Background: Previous research has raised substantial concerns regarding the validity of the International Statistical Classification of Diseases and Related Health Problems (ICD) codes (ICD-10 I05–I09) for rheumatic heart disease (RHD) due to likely misclassification of non-rheumatic valvular disease (non-rheumatic VHD) as RHD. There is currently no validated, quantitative approach for reliable case ascertainment of RHD in administrative hospital data. Methods: A comprehensive dataset of validated Australian RHD cases was compiled and linked to inpatient hospital records with an RHD ICD code (2000– 2018, n=7555). A prediction model was developed based on a generalized linear mixed model structure considering an extensive range of demographic and clinical variables. It was validated internally using randomly selected cross-validation samples and externally. Conditional optimal probability cutpoints were calculated, maximising discrimination separately for high-risk versus low-risk populations. Results: The proposed model reduced the false-positive rate (FPR) from acute rheumatic fever (ARF) cases misclassified as RHD from 0.59 to 0.27; similarly for non-rheumatic VHD from 0.77 to 0.22. Overall, the model achieved strong discriminant capacity (AUC: 0.93) and maintained a similar robust performance during external validation (AUC: 0.88). It can also be used when only basic demographic and diagnosis data are available. Conclusion: This paper is the first to show that not only misclassification of non-rheumatic VHD but also of ARF as RHD yields substantial FPRs. Both sources of bias can be successfully addressed with the proposed model which provides an effective solution for reliable RHD case ascertainment from hospital data for epidemiological disease monitoring and policy evaluation.